Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin.

• Phase: Phase 2

Details

• Lead Sponsor: Novartis
• Treatments: Darifenacin; Mandelic Acids; Oxybutynin

Criteria

Inclusion Criteria:

• Males and females aged 60 and over

• United States English as a primary language

• Given written informed consent by signing and dating an informed consent form prior to study entry

Exclusion Criteria:

• Current diseases in which the use of anti-cholinergic drugs is contraindicated, including the use of drugs with anti-cholinergic effects

• Volunteers with history of urinary retention or current bladder outlet obstruction, as determined by the investigator

Other protocol defined inclusion/exclusion criteria may apply.

• Current use of drugs known to effect memory and cognition Other protocol-defined inclusion/exclusion criteria may apply